As the cutting-edge equipment is able to process multiple samples simultaneously, the team will also be able to validate over 100 biomarkers in one year, as compared to 10 biomarkers over five years using the conventional method.
Assistant Professor Newman Sze, from NTU's School of Biological Sciences, lead researcher of the project, said the local study will take one year and will involve some 2,000 samples collected in Singapore and the Netherlands.
"After discovering that such biomarkers exist, we need to validate them further to ascertain that people with these proteins are really at a risk of heart attack and stroke. This approach is expected to lead to the development of new and improved tools for early diagnosis of heart attack and stroke patients, way before the diseases strike," said Prof. Sze.
Dr. Vitaly Sorokin, part of the team at the NUH involved in this research, said that Singapore is a good place to validate these biomarkers, as this is a unique opportunity to involve and compare results among the multi-racial population.
"This biomarkers which allows prediction of major cardiovascular events, carries great benefits for the doctors, and will likely lead to the development of prevention strategies or algorithm which will give us a chance to stop heart complications from happening or to improve the clinical outcome of treatment," said Dr. Sorokin, a Russian.
"Having the opportunity to screen and diagnose condition like myocardial infarction and stroke, will give doctors time to prevent the complication of atherosclerosis the hardening of arteries which causes heart attacks and strokes. With such a technology, patients with known conditions like ischemic heart disease and cerebro-vascular disease can be monitored more effectively."
Coronary heart disease and stroke are majo
|Contact: Lester Kok|
Nanyang Technological University